Valuation: Avicanna Inc.

Market Cap 16.8M 11.96M 10.39M 9.7M 8.91M 1.14B 17.09M 114M 44.82M 568M 44.92M 43.93M 1.88B P/E 2024
-8.43x
P/E 2025 -9.36x
Enterprise Value 16.52M 11.76M 10.22M 9.54M 8.76M 1.12B 16.81M 113M 44.07M 559M 44.17M 43.19M 1.84B EV / Sales 2024
1.31x
EV / Sales 2025 1.03x
Free-Float
77.41%
Yield 2024 *
-
Yield 2025 -
1 day+7.33%
1 week-6.93%
1 month+4.27%
3 months-15.73%
6 months-38.16%
Current year-42.81%
1 week 0.09
Extreme 0.0852
0.1
1 month 0.07
Extreme 0.0684
0.1
Current year 0.07
Extreme 0.0684
0.18
1 year 0.07
Extreme 0.0684
0.24
3 years 0.07
Extreme 0.0684
0.53
5 years 0.07
Extreme 0.0684
1.08
10 years 0
Extreme 0
3.53
Manager TitleAgeSince
Sales & Marketing - 01/05/2015
Chief Executive Officer 39 26/11/2016
Director of Finance/CFO - 15/09/2025
Director TitleAgeSince
Chairman 39 26/11/2016
Director/Board Member - 22/10/2018
Director/Board Member - 01/01/2026
Change 5-day change 1-year change 3-year change Capi.($)
+7.33%-6.93% - - 11.97M
-0.36%+0.14%-0.95%+14.33% 48.53B
-2.53%-2.45%+393.44%+475.29% 39.87B
-1.25%+8.86%+27.01%+7.31% 38.68B
-1.43%-4.66%+2.11%+50.96% 35.13B
-2.41%+2.59%+11.68%+41.16% 29.79B
-0.72%-2.65%+32.67%+122.34% 16.11B
+0.30%-4.11% - - 16.08B
-0.62%+1.23%+1.80%+15.05% 13.61B
-4.08%-7.17%-4.93%-37.59% 12.62B
Average -0.48%+0.86%+57.85%+86.11% 27.82B
Weighted average by Cap. -1.26%+1.82%+75.08%+105.17%

Financials

2024 2025
Net sales 25.46M 18.13M 15.75M 14.71M 13.5M 1.73B 25.9M 173M 67.92M 862M 68.09M 66.58M 2.84B 25.48M 18.14M 15.77M 14.72M 13.51M 1.73B 25.92M 174M 67.97M 862M 68.14M 66.63M 2.84B
Net income -3.62M -2.58M -2.24M -2.09M -1.92M -246M -3.68M -24.64M -9.65M -122M -9.68M -9.46M -404M -2.76M -1.96M -1.71M -1.59M -1.46M -187M -2.81M -18.8M -7.36M -93.38M -7.38M -7.22M -308M
Net Debt -339K -241K -210K -196K -180K -22.99M -345K -2.31M -904K -11.47M -906K -886K -37.82M -281K -200K -174K -162K -149K -19.04M -286K -1.91M -749K -9.5M -751K -734K -31.33M
Logo Avicanna Inc.
Avicanna Inc. is a commercial-stage international biopharmaceutical company. It focuses on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Its products and services are grouped into four main categories, such as medical cannabis products; MyMedi.ca medical cannabis platform; pharmaceutical pipeline; and active pharmaceutical ingredients. The formulary of proprietary medical cannabis products is marketed under the RHO Phyto brand and offers a range of scientifically driven formulations in a variety of products, including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids. MyMedi.ca offers a diverse portfolio of products and bilingual pharmacist-led patient support programs. It has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. Trunerox is its oral formulation.
Employees
112
Date Price Change Volume
31/07/26 $0.0927 +7.33% 1,000
30/07/26 $0.0864 -10.59% 35,711
29/07/26 $0.0966 +4.32% 6,725
28/07/26 $0.0926 -3.64% 1,100
27/07/26 $0.0961 -3.51% 106,000